<p>Fisher Funds Management LTD 在最近向美国证券交易委员会（SEC）披露的文件中表示，在第四季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的持股减少了 14.2%。该基金在此期间出售了 125,697 股后，持有 761,899 股该医疗研究公司的股票。爱德华生命科学占 Fisher Funds Management LTD 投资组合的约 1.7%，是其第 16 大持股。Fisher Funds Management LTD 在最近的报告期末持有的爱德华生命科学股份约占 0.13%，价值 65,150,000 美元。</p>
<p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
<ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
<p>其他大型投资者也买卖了该公司的股票。JPL Wealth Management LLC 在第三季度购买了价值约 25,000 美元的爱德华生命科学新股份。True Wealth Design LLC 在第三季度将其在爱德华生命科学的持股增加了 251.5%。True Wealth Design LLC 现在持有 362 股该医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 259 股。Hantz Financial Services Inc. 在第三季度将其在爱德华生命科学的持股增加了 76.6%。Hantz Financial Services Inc. 现在持有 378 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 164 股。Dorato Capital Management 在第四季度购买了价值约 29,000 美元的爱德华生命科学新股份。最后，Rakuten Securities Inc. 在第二季度将其在爱德华生命科学的持股增加了 413.7%。Rakuten Securities Inc. 现在持有 375 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 302 股。79.46% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司最近对 EW 进行了评估。高盛集团在 2 月 11 日的报告中重申了对爱德华生命科学的 “买入” 评级，并将目标价设定为 95.00 美元（低于 108.00 美元）。瑞穗证券在周一的报告中将爱德华生命科学的目标价设定为 95.00 美元，并给予公司 “跑赢大盘” 的评级。瑞银集团在 2 月 4 日的报告中重申了对爱德华生命科学的 “中性” 评级，并将目标价设定为 94.00 美元。罗伯特·W·贝尔德在 1 月 12 日的报告中将爱德华生命科学的目标价设定为 90.00 美元。最后，派珀·桑德勒在 2 月 11 日的报告中重申了对爱德华生命科学的 “增持” 评级，并将目标价设定为 100.00 美元（高于 98.00 美元）。三位投资分析师对该股票给予了强烈买入评级，十六位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 95.74 美元。</p>
<ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
<p><strong>阅读我们对爱德华生命科学的最新分析</strong></p>
<h2>爱德华生命科学的内部活动</h2>
<p>在其他爱德华生命科学的新闻中，副总裁 Daniel J. Lippis 在 4 月 6 日（星期一）出售了 1,019 股公司的股票。股票以平均价格 80.98 美元出售，总价值为 82,518.62 美元。交易完成后，该副总裁直接持有 33,934 股公司股票，价值 2,747,975.32 美元。这代表了他们持股的 2.92% 的减少。该交易在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，副总裁 Donald E. Bobo, Jr.在 4 月 2 日（星期四）出售了 22,680 股公司的股票。股票以平均价格 80.16 美元出售，总交易额为 1,818,028.80 美元。交易完成后，该副总裁持有 21,266 股公司的股票，价值约 1,704,682.56 美元。该交易是他们持股的 51.61% 的减少。SEC 对此次出售的文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 7,118,636 美元的 86,058 股公司股票。0.31% 的股票由公司内部人士持有。</p>
<h2>爱德华生命科学股票表现</h2>
<ul>
<li>3 只具有长期顺风的医疗行业开创者</li>
</ul>
<p>爱德华生命科学（NYSE:EW - 获取免费报告）周五开盘价为 78.90 美元。该公司的 50 日移动平均线为 81.23 美元，200 日移动平均线为 82.03 美元。公司当前比率为 3.72，速动比率为 3.09，债务与股本比率为 0.06。该公司的市值为 454.9 亿美元，市盈率为 43.11，市盈增长比率为 2.04，贝塔值为 0.95。爱德华生命科学公司 12 个月低点为 68.63 美元，12 个月高点为 87.89 美元。</p>
<p>爱德华生命科学（NYSE:EW - 获取免费报告）最后一次公布财报是在 2 月 10 日（星期二）。该医疗研究公司报告每股收益（EPS）为 0.58 美元，低于共识预期的 0.62 美元（差额为 0.04 美元）。该公司在本季度的收入为 15.7 亿美元，而共识预期为 15.4 亿美元。爱德华生命科学的净利润率为 17.69%，股本回报率为 14.50%。该公司的季度收入同比增长 13.3%。在去年同期，该公司每股收益为 0.59 美元。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 EPS。研究分析师预计爱德华生命科学公司今年的每股收益将达到 2.45 美元。</p>
<h2>爱德华生命科学公司简介</h2>
<p>（免费报告）</p>
<p>爱德华生命科学是一家专注于结构性心脏病和重症监护产品及疗法的医疗科技公司。该公司设计、开发并制造用于外科手术和微创（经导管）手术的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点是能够替代开放心脏手术的经导管主动脉瓣置换（TAVR）技术。</p>
<p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
<p>在你考虑爱德华生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爱德华生命科学并不在名单上。</p>
<p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

爱德华生命科学

标普健康医疗设备 ETF - SPDR

美国医药设备 ETF - iShares

<p>Fisher Funds Management LTD 在第四季度将其在爱德华生命科学（NYSE:EW）公司的持股减少了 14.2%，目前持有 761,899 股，出售了 125,697 股。这占其投资组合的约 1.7%，价值为 6515 万美元。其他投资者也调整了他们的持仓，显著增加和新购入的情况屡见不鲜。分析师对爱德华生命科学维持 “适度买入” 的共识评级，平均目标价为 95.74 美元。近期还报告了内部人士的销售情况，显示高管之间的交易活跃</p>

<p>Fisher Funds Management LTD cut its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 14.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 761,899 shares of the medical research company's stock after selling 125,697 shares during the period. Edwards Lifesciences makes up about 1.7% of Fisher Funds Management LTD's investment portfolio, making the stock its 16th largest holding. Fisher Funds Management LTD owned about 0.13% of Edwards Lifesciences worth $65,150,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Fisher Funds Management LTD 在最近向美国证券交易委员会（SEC）披露的文件中表示，在第四季度将其在爱德华生命科学公司（NYSE:EW - 免费报告）的持股减少了 14.2%。该基金在此期间出售了 125,697 股后，持有 761,899 股该医疗研究公司的股票。爱德华生命科学占 Fisher Funds Management LTD 投资组合的约 1.7%，是其第 16 大持股。Fisher Funds Management LTD 在最近的报告期末持有的爱德华生命科学股份约占 0.13%，价值 65,150,000 美元。</p>
</div><p>Get <strong>Edwards Lifesciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>爱德华生命科学</strong> 的提醒：</p>
</div><ul>
<li>A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBH</li>
</ul>
<div class="lb-trans"><ul>
<li>深入分析医疗行业收益：AZN vs. EW vs. ZBH</li>
</ul>
</div><p>Other large investors have also bought and sold shares of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter valued at approximately $25,000. True Wealth Design LLC raised its holdings in shares of Edwards Lifesciences by 251.5% during the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock valued at $28,000 after purchasing an additional 259 shares during the last quarter. Hantz Financial Services Inc. raised its holdings in shares of Edwards Lifesciences by 76.6% during the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock valued at $29,000 after purchasing an additional 164 shares during the last quarter. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $29,000. Finally, Rakuten Securities Inc. raised its holdings in shares of Edwards Lifesciences by 413.7% during the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock valued at $29,000 after purchasing an additional 302 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他大型投资者也买卖了该公司的股票。JPL Wealth Management LLC 在第三季度购买了价值约 25,000 美元的爱德华生命科学新股份。True Wealth Design LLC 在第三季度将其在爱德华生命科学的持股增加了 251.5%。True Wealth Design LLC 现在持有 362 股该医疗研究公司的股票，价值 28,000 美元，此前在上个季度又购买了 259 股。Hantz Financial Services Inc. 在第三季度将其在爱德华生命科学的持股增加了 76.6%。Hantz Financial Services Inc. 现在持有 378 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 164 股。Dorato Capital Management 在第四季度购买了价值约 29,000 美元的爱德华生命科学新股份。最后，Rakuten Securities Inc. 在第二季度将其在爱德华生命科学的持股增加了 413.7%。Rakuten Securities Inc. 现在持有 375 股该医疗研究公司的股票，价值 29,000 美元，此前在上个季度又购买了 302 股。79.46% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have recently weighed in on EW. The Goldman Sachs Group reissued a &#34;buy&#34; rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Mizuho set a $95.00 price objective on shares of Edwards Lifesciences and gave the company an &#34;outperform&#34; rating in a report on Monday. UBS Group reissued a &#34;neutral&#34; rating and set a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Piper Sandler reissued an &#34;overweight&#34; rating and set a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $95.74.</p>
<div class="lb-trans"><p>几家研究公司最近对 EW 进行了评估。高盛集团在 2 月 11 日的报告中重申了对爱德华生命科学的 “买入” 评级，并将目标价设定为 95.00 美元（低于 108.00 美元）。瑞穗证券在周一的报告中将爱德华生命科学的目标价设定为 95.00 美元，并给予公司 “跑赢大盘” 的评级。瑞银集团在 2 月 4 日的报告中重申了对爱德华生命科学的 “中性” 评级，并将目标价设定为 94.00 美元。罗伯特·W·贝尔德在 1 月 12 日的报告中将爱德华生命科学的目标价设定为 90.00 美元。最后，派珀·桑德勒在 2 月 11 日的报告中重申了对爱德华生命科学的 “增持” 评级，并将目标价设定为 100.00 美元（高于 98.00 美元）。三位投资分析师对该股票给予了强烈买入评级，十六位给予了买入评级，九位给予了持有评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，共识目标价为 95.74 美元。</p>
</div><ul>
<li>Beyond Biotech—3 Healthcare Stocks for Growth-Minded Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>超越生物技术——3 只适合成长型投资者的医疗股票</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Edwards Lifesciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们对爱德华生命科学的最新分析</strong></p>
</div><h2>Insider Activity at Edwards Lifesciences</h2>
<div class="lb-trans"><h2>爱德华生命科学的内部活动</h2>
</div><p>In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the company's stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the company's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the transaction, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他爱德华生命科学的新闻中，副总裁 Daniel J. Lippis 在 4 月 6 日（星期一）出售了 1,019 股公司的股票。股票以平均价格 80.98 美元出售，总价值为 82,518.62 美元。交易完成后，该副总裁直接持有 33,934 股公司股票，价值 2,747,975.32 美元。这代表了他们持股的 2.92% 的减少。该交易在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，副总裁 Donald E. Bobo, Jr.在 4 月 2 日（星期四）出售了 22,680 股公司的股票。股票以平均价格 80.16 美元出售，总交易额为 1,818,028.80 美元。交易完成后，该副总裁持有 21,266 股公司的股票，价值约 1,704,682.56 美元。该交易是他们持股的 51.61% 的减少。SEC 对此次出售的文件提供了更多信息。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士出售了价值 7,118,636 美元的 86,058 股公司股票。0.31% 的股票由公司内部人士持有。</p>
</div><h2>Edwards Lifesciences Stock Performance</h2>
<div class="lb-trans"><h2>爱德华生命科学股票表现</h2>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只具有长期顺风的医疗行业开创者</li>
</ul>
</div><p>Shares of NYSE EW opened at $78.90 on Friday. The firm has a 50 day moving average of $81.23 and a 200 day moving average of $82.03. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $45.49 billion, a price-to-earnings ratio of 43.11, a price-to-earnings-growth ratio of 2.04 and a beta of 0.95. Edwards Lifesciences Corporation has a 12-month low of $68.63 and a 12-month high of $87.89.</p>
<div class="lb-trans"><p>爱德华生命科学（NYSE:EW - 获取免费报告）周五开盘价为 78.90 美元。该公司的 50 日移动平均线为 81.23 美元，200 日移动平均线为 82.03 美元。公司当前比率为 3.72，速动比率为 3.09，债务与股本比率为 0.06。该公司的市值为 454.9 亿美元，市盈率为 43.11，市盈增长比率为 2.04，贝塔值为 0.95。爱德华生命科学公司 12 个月低点为 68.63 美元，12 个月高点为 87.89 美元。</p>
</div><p>Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The business had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business's quarterly revenue was up 13.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.</p>
<div class="lb-trans"><p>爱德华生命科学（NYSE:EW - 获取免费报告）最后一次公布财报是在 2 月 10 日（星期二）。该医疗研究公司报告每股收益（EPS）为 0.58 美元，低于共识预期的 0.62 美元（差额为 0.04 美元）。该公司在本季度的收入为 15.7 亿美元，而共识预期为 15.4 亿美元。爱德华生命科学的净利润率为 17.69%，股本回报率为 14.50%。该公司的季度收入同比增长 13.3%。在去年同期，该公司每股收益为 0.59 美元。爱德华生命科学已将其 2026 年第一季度的指导目标设定为 0.700-0.760 EPS。研究分析师预计爱德华生命科学公司今年的每股收益将达到 2.45 美元。</p>
</div><h2>Edwards Lifesciences Company Profile</h2>
<div class="lb-trans"><h2>爱德华生命科学公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.</p>
<div class="lb-trans"><p>爱德华生命科学是一家专注于结构性心脏病和重症监护产品及疗法的医疗科技公司。该公司设计、开发并制造用于外科手术和微创（经导管）手术的心脏瓣膜及相关输送系统。其产品组合涵盖多种瓣膜疾病，重点是能够替代开放心脏手术的经导管主动脉瓣置换（TAVR）技术。</p>
</div><p>In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.</p>
<div class="lb-trans"><p>除了经导管心脏瓣膜——包括广为人知的 SAPIEN 系列——爱德华还提供外科组织瓣膜和心脏外科医生、介入心脏病专家及医院团队使用的辅助设备。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Edwards Lifesciences</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比爱德华生命科学更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUVX" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=EW"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Edwards Lifesciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在爱德华生命科学吗？</h2>
</div><p>Before you consider Edwards Lifesciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑爱德华生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而爱德华生命科学并不在名单上。</p>
</div><p>While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然爱德华生命科学目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Fisher Funds Management LTD Decreases Position in Edwards Lifesciences Corporation $EW

Market Beat

Rakuten Group, Inc.

乐天集团(ADR)

阿斯利康

阿斯利康制药

Zimmer Biomet

高盛

Mizuho Financial Group, Inc.

瑞穗金融集团

瑞银集团

Piper Sandler Cos

GS Hldg R

Fisher Funds Management LTD 减少了其在爱德华生命科学公司 $EW 的持仓